Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Depreciation & Amortization (CF): 2015-2024

Historic Depreciation & Amortization (CF) for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to $113,859.

  • Outlook Therapeutics' Depreciation & Amortization (CF) fell 90.98% to $80,149 in Q3 2020 from the same period last year, while for Sep 2020 it was $554,069, marking a year-over-year decrease of 83.52%. This contributed to the annual value of $113,859 for FY2024, which is 157.67% up from last year.
  • According to the latest figures from FY2024, Outlook Therapeutics' Depreciation & Amortization (CF) is $113,859, which was up 157.67% from $44,188 recorded in FY2023.
  • Outlook Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $554,069 during FY2020, with a 5-year trough of $44,188 in FY2023.
  • For the 3-year period, Outlook Therapeutics' Depreciation & Amortization (CF) averaged around $120,914, with its median value being $113,859 (2024).
  • Per our database at Business Quant, Outlook Therapeutics' Depreciation & Amortization (CF) slumped by 83.52% in 2020 and then surged by 157.67% in 2024.
  • Yearly analysis of 5 years shows Outlook Therapeutics' Depreciation & Amortization (CF) stood at $554,069 in 2020, then crashed by 52.69% to $262,140 in 2021, then decreased by 21.91% to $204,694 in 2022, then plummeted by 78.41% to $44,188 in 2023, then soared by 157.67% to $113,859 in 2024.